The Global IVF Landscape: A Comprehensive Analysis of Cost, Access, and Affordability

By CARE Fertility and Women's Health

July 29, 2025

Introduction: The High Stakes of Building a Family

The journey to parenthood is increasingly intersecting with advanced medical technology, with In Vitro Fertilization (IVF) becoming a critical pathway for millions globally. However, access to this life-changing treatment is not uniform. It is shaped by a complex interplay of national healthcare policies, economic realities, and regulatory frameworks, creating a fragmented global landscape of opportunity and disparity. One in six heterosexual couples worldwide experience infertility, and many single individuals and same-sex couples also require assisted reproductive technology (ART) to build their families.¹ Yet, the ability to access care is often dictated more by geography and wealth than by medical need. The financial burden can be immense, with costs varying dramatically not just between countries, but within them, creating systems of unequal access.

This report provides an exhaustive analysis of the global IVF market. We will first deconstruct the "true cost" of an IVF cycle, moving beyond advertised prices to reveal a complex web of necessary expenses. We will then conduct a comparative affordability analysis, indexing these costs against local income and living standards to measure the real financial impact on patients in the United States, Canada, the United Kingdom, Australia, Spain, Denmark, Japan, and India. The core of this analysis will be an examination of how different funding models—private-pay, public, and two-tier systems—dictate access, create disparities in wait times and patient experience, and ultimately fuel the burgeoning market of fertility tourism.

Section 1: Deconstructing the Cost of an IVF Cycle: Beyond the Advertised Price

The term "cost of IVF" is a profound misnomer; it is rarely a single, transparent price but rather a cumulative total of numerous, often non-optional, services and procedures. Understanding the full financial scope of treatment is the first critical step for any prospective patient.

The Anatomy of an IVF Bill: The Iceberg of Expenses

The advertised base cost of a single IVF cycle often represents only the tip of a financial iceberg. In the United States, the base fee is estimated to be between $14,000 and $20,000.³ In the UK, the average advertised package is around £3,898.⁵ However, these figures are merely starting points. Analysis reveals that the "true cost" of a single cycle, once all necessary components are included, is significantly higher. In the UK, this true cost averages £5,310—36% more than advertised—and in a high-cost city like London, the markup is even starker, with a true cost of £6,150 being 57% higher than the advertised price.⁵ This discrepancy arises from a collection of essential services and variable costs that are often excluded from the initial quote.

These mandatory additions and variable costs include:

1. Medications: A substantial and unavoidable expense, fertility drugs are required to stimulate the ovaries, promote follicle development, and support implantation. These can add $3,000 to $6,000 to a cycle in the US, $5,000 to $7,000 CAD in Canada, and an average of £1,600 in the UK.³ In India, these injections can range from ₹50,000 to ₹1,00,000.⁸

2. Consultations and Monitoring: The journey begins with initial consultations, which can cost $225-$500 in the US or £230 in the UK, with follow-up appointments adding to the bill.⁴

3. Anesthesia: General anesthesia or sedation is required for the egg retrieval procedure, adding another $500 to $1,500 in the US.³

4. Laboratory Procedures: Intracytoplasmic Sperm Injection (ICSI), a technique where a single sperm is injected directly into an egg, is a common addition, particularly in cases of male factor infertility. This procedure alone can cost $1,000-$2,500 in the US, $1,500-$3,000 CAD in Canada, or £1,300 in the UK.³ Other lab techniques like blastocyst culture, which involves growing embryos for a longer period, can add further costs, such as £560 in the UK.⁵

Beyond these core components, a suite of advanced and optional services can escalate the total price dramatically:

• Preimplantation Genetic Testing (PGT): This technology, used to screen embryos for genetic or chromosomal abnormalities, is a major cost driver. The use of PGT is cited as a reason for a 10–15% annual increase in total IVF prices.⁹ In the US, PGT for aneuploidy (PGT-A) costs between $2,500 and $4,000, while more complex testing for single gene disorders (PGT-M) can range from $7,000 to $12,000 per cycle.³ In Australia, PGT-A costs approximately $770 per embryo, with a cap for multiple embryos from the same cycle.¹⁰

• Cryopreservation and Storage: Freezing surplus embryos for future use is now standard practice. The initial freezing procedure can cost $2,000–$4,000 in the US, with subsequent annual storage fees ranging from $500 to $1,000.³ In India, the initial cryopreservation can be as high as ₹1,40,000, with annual storage fees on top of that.¹¹

• Third-Party Reproduction: The need for donor gametes or a gestational carrier significantly increases the financial commitment. In the US, using donor eggs can add $20,000 to $45,000 to the total cost, while using donor sperm is more modest, typically ranging from $400 to $2,500.³

This multi-faceted cost structure creates a significant information asymmetry between clinics and patients. In an emotionally charged and medically complex environment, patients may find it difficult to navigate opaque pricing and distinguish between necessary procedures and optional, sometimes unproven, add-ons.

The Multi-Cycle Reality: The True Cost of a Baby

Perhaps the most critical financial reality of IVF is that success is rarely achieved in a single attempt. Data from the US indicates that the average patient undergoes between 2.3 and 2.7 IVF cycles to achieve a live birth.⁹ This fundamentally reframes the financial calculation. The total expenditure is not the single-cycle cost of around $23,000, but an average total outlay closer to $50,000.⁹

Subsequent attempts may involve a Frozen Embryo Transfer (FET), which utilizes embryos cryopreserved from a previous fresh cycle. While an FET is less expensive than a full stimulation cycle—costing between $4,330 and $6,940 in the US⁴ or around $4,212 AUD in Australia¹²—it still represents a significant additional expense.

The high cost of a failed cycle creates immense psychological and financial pressure to ensure the next one succeeds. This pressure can make patients more receptive to clinic recommendations for expensive add-on technologies, even if their efficacy is debated.¹³ A feedback loop is thus created where the high cost of failure drives up the cost of subsequent attempts, turning a large one-time expense into a potentially prolonged and financially draining commitment. This dynamic is a key feature of the patient experience, particularly in private-pay markets where the financial risk is borne entirely by the individual.

Section 2: A Global Comparative Analysis of IVF Affordability

A direct comparison of IVF prices across countries, converted to a single currency, provides an initial snapshot of the global market. However, to understand the true accessibility of treatment, these absolute costs must be contextualized against local economic conditions.

Sticker Shock: A Cross-Country Price Comparison

When estimating the "all-in" cost for a single, comprehensive IVF cycle—including the base fee, medications, and a standard ICSI procedure—a clear hierarchy of pricing emerges. Converting local currencies to US dollars reveals vast disparities:

• High-Cost Tier: The United States stands alone as the most expensive market, with an all-in cycle costing between $25,000 and $30,000.³ Australia also falls into a higher-cost category, with a private ICSI cycle costing around $13,691 AUD. Even with Medicare rebates, the out-of-pocket expense for a first cycle can be approximately $7,468 AUD, or roughly $5,000 USD.¹⁰

• Mid-Cost Tier: Canada’s private system prices a comprehensive cycle between $15,000 and $25,000 CAD, which translates to approximately $11,000 to $18,000 USD.⁷ In the UK, a privately funded cycle with add-ons averages around £9,420, or about $12,000 USD.⁵

• Lower-Cost Tier: European destinations offer significantly lower prices. In Spain, a cycle with own eggs ranges from €4,100 to €7,100, with an all-in cost likely falling between $6,000 and $9,000 USD after accounting for medications and ICSI.¹⁴ Denmark is similarly priced, with a base cycle from €3,300 to €4,500, suggesting a total cost of $5,000 to $7,000 USD.¹⁶ Japan, following its 2022 insurance reform, has a remarkably low out-of-pocket cost, with a base cycle around ¥500,000 ($3,400 USD), though this is before adding non-covered advanced procedures.¹⁸

• Lowest-Cost Tier: India offers the lowest absolute prices, with an average all-in cycle ranging from ₹2,00,000 to ₹3,00,000, or approximately $2,400 to $3,600 USD.⁸

This raw price comparison is the primary driver of fertility tourism, where patients from high-cost nations like the US travel to lower-cost destinations like Spain or India to reduce their financial burden.¹⁹

Indexing for Reality: IVF vs. The Economic Landscape

Absolute cost is a misleading indicator of affordability for a country’s residents. A $10,000 procedure represents a different level of financial strain in a nation with an average annual income of $60,000 versus one with an income of $20,000. To measure this burden, this report utilizes an IVF Affordability Index, calculated by dividing the estimated all-in cost of one IVF cycle by the country’s average annual household disposable income per capita.²¹ A higher index value signifies a greater financial burden, representing the fraction of an average person’s annual income required to pay for one treatment cycle.

Note: Income for India is based on NNI per capita at current prices for 2023-24. All-in IVF cost is an estimate for a comprehensive private cycle.

The affordability landscape revealed by this index is nearly an inversion of the absolute cost ranking.

• The Indian Paradox: Despite having the world's cheapest IVF in absolute terms, India presents a catastrophic affordability crisis for its own population. An affordability index of 1.36 means a single IVF cycle costs significantly more than the average citizen's entire annual income. This extreme unaffordability has profound implications for the structure of its domestic market.

• High-Income Affordability: In contrast, high-income European nations and Japan demonstrate remarkable affordability for their residents. Denmark and Japan have the lowest affordability indices (0.14 and 0.12, respectively), meaning a cycle costs just over 10% of an average person's annual disposable income. Australia and Spain also show strong affordability.

• The Anglosphere Middle Ground: The US, UK, and Canada sit in the middle. The US has the highest index in this group (0.41), meaning a cycle consumes over 40% of an average annual income, a substantial but not insurmountable burden for many households, especially given higher absolute incomes.

This analysis reveals a critical dynamic: the structure of a country's IVF industry is a direct consequence of its affordability for the local population. In India, the market model is necessarily bifurcated. It caters almost exclusively to two segments: a small, wealthy domestic elite and a large, growing market of international fertility tourists who can leverage global income disparities.¹⁹ The "low cost" of Indian IVF is a feature designed for the global market, not a benefit for the local majority. This explains the recent influx of venture capital into the Indian fertility sector, which aims to build tech-enabled platforms to capture this dual market of affluent Indians and foreigners.²⁶

Section 3: The Great Divide: Public, Private, and Two-Tier Funding Systems

The affordability of IVF is inextricably linked to national healthcare policy. The extent to which a government chooses to fund or subsidize treatment determines who can access it and under what conditions. Globally, three primary models emerge: private-pay, publicly funded, and two-tier hybrid systems.

Category 1: The Private-Pay Landscape (USA & India)

In these markets, the financial burden of IVF falls almost entirely on the individual.

• United States: The US system is characterized by a near-total reliance on out-of-pocket payments or private insurance coverage, which is notoriously inconsistent and often inadequate.²⁹ This market-driven approach results in the highest absolute costs in the world.³ The industry is highly commercialized, with clinics actively marketing financing options, loans, and multi-cycle "packages" as part of their business model.³ While non-profit organizations like the BabyQuest Foundation provide financial grants, these are limited in number and highly competitive, offering a lifeline to only a fraction of those in need.²⁹

• India: While some state governments, such as in Tamil Nadu and Goa, have launched initiatives to provide free or heavily subsidized IVF for low-income families, these programs are not widespread and access is limited.³⁰ The market is overwhelmingly dominated by a rapidly growing private sector.⁸ This sector is currently experiencing significant investment and consolidation, driven by venture capital firms aiming to build national brands that serve both affluent Indians and the lucrative international patient market.²⁶ Charitable support, such as the ISAR Dr Sadhana Desai Endowment Fund, exists but provides only partial aid (₹50,000) to a limited number of applicants.³²

Category 2: The Publicly Funded Model (Spain & Denmark)

These nations integrate fertility treatment into their public healthcare systems, though access is not unlimited.

• Spain: The public health system offers free access to IVF. In a significant policy shift in 2021, this access was expanded to include single women, lesbians, and transgender people, ending a period of restriction to only heterosexual couples.³³ However, public access is governed by eligibility criteria, such as age limits, which can vary by region. For example, the Community of Madrid raised the age limit for public access from 40 to 45.³⁵ Despite this robust public system, patients can face long waiting lists of one to two years.³⁶ This, combined with Spain's liberal laws on issues like donor anonymity, has made it a massive international hub for private fertility tourism, creating a de facto two-tier system where a public system serves residents while a private system serves the global market.¹⁴

• Denmark: The Danish public system provides significant support, covering fertility evaluation and intrauterine insemination (IUI) for residents with a Danish CPR number who are referred before the woman turns 40.³⁸ As of 2024, the government expanded free fertility treatment to cover a second child, offering up to six IVF attempts for the first child and three for the second at public hospitals.³⁹ However, patients must still pay for their own medications and any donor sperm required.³⁸ Furthermore, while a referral can be made to a public hospital for IVF, many patients opt for treatment at private clinics, where the IVF procedure itself is self-funded.³⁸ This creates a hybrid model where the state covers diagnostics and some treatments, but significant costs, including the core IVF procedure for many, remain in the private domain.

Category 3: The Two-Tier System Dilemma (UK, Canada, Australia, Japan)

These countries have complex hybrid systems where public and private sectors coexist and interact, creating unique challenges and inequalities.

• United Kingdom: The UK is the classic example of a two-tier system defined by the "postcode lottery".⁴² The National Health Service (NHS) provides a number of funded IVF cycles, but both eligibility and the number of cycles offered (ranging from zero to the three recommended by the National Institute for Health and Care Excellence, or NICE) are determined by local Integrated Care Boards (ICBs).⁴² This results in vast regional disparities. Access is often restricted by strict non-clinical criteria, such as age, Body Mass Index (BMI), smoking status, and whether a partner has existing children.⁴⁵ The combination of inconsistent funding and notoriously long waiting lists forces a majority of patients—six out of ten—into the private sector.⁴⁷

• Canada: Canada's system is a "provincial patchwork" of different policies, leading to profound inter-provincial inequality.¹ Ontario funds one IVF cycle per lifetime, but does not cover medications (approx. $5,000 CAD).¹ Quebec also funds one cycle but includes medication coverage.¹ In 2025, British Columbia launched a new, income-tested program that provides up to $19,000 CAD towards a cycle for those earning under $100,000 CAD.⁵¹ Manitoba and Nova Scotia offer a 40% tax credit on fertility expenses.¹ Meanwhile, Alberta is the only province with no public funding program at all.¹ This fragmented approach creates long waitlists for the limited funded spots and drives a robust parallel private system.⁵⁴

• Australia: Australia operates a rebate-based two-tier system. Medicare, the universal health insurance scheme, provides substantial rebates for a wide range of out-of-hospital IVF-related services, significantly reducing the out-of-pocket cost for patients using private clinics.⁵⁷ For example, an ICSI cycle costing $13,691 AUD can have a final out-of-pocket expense of around $7,468 AUD after rebates.¹⁰ However, Medicare does not cover all costs; hospital admission fees, some medications, and embryo storage remain private expenses.⁵⁷ To address remaining gaps, some states like Victoria are now launching fully public fertility care services targeted at low-income Victorians and other specific groups, further segmenting the market.⁵⁹

• Japan: Japan has recently reformed its system into a co-payment insurance model. In a major policy shift in April 2022 aimed at combating the country's declining birthrate, the government began covering 70% of the costs for standard IVF treatments under its public health insurance program.⁶⁰ This dramatically lowered the financial barrier for a broad population. However, coverage is not all-encompassing. It is limited by the woman's age (under 43) and the number of cycles, and it explicitly excludes "advanced medical care" such as PGT, which must be paid for entirely out-of-pocket.⁶² To bridge this gap, many local municipal governments offer additional subsidies to help residents cover the remaining 30% co-payment or the cost of non-covered advanced procedures.⁶²

The design of a country's funding system does more than provide a safety net; it is the primary architect of the private market's structure and incentives. In the UK and Canada, long waits for free public cycles create a private market based on selling speed. In Australia, universal rebates for private care make the private market the default system, with fully public care being a niche for the disadvantaged. In Japan, public insurance covering 70% of the cost makes private care more affordable for everyone, reducing the incentive for risky cost-cutting or medical tourism. The public policy is not just an alternative to the private market; it actively defines the private market's value proposition.

Section 4: The Human Cost of Two-Tier Systems: Wait Times and Unequal Access

While two-tier systems are often created with the intention of expanding access, their practical implementation can create significant inequities and place a heavy burden on patients. The most pronounced challenges—wait times and unequal access—are starkly illustrated in the systems of the United Kingdom and Canada.

The Waiting Game: Time as a Clinical Factor

The most significant and consequential difference between public and private pathways in a two-tier system is time. For those seeking fertility treatment, this is not merely an inconvenience; it is a critical clinical variable.

• Public vs. Private Timelines: In the UK, the wait for NHS-funded treatment can be agonizingly long. After a referral from a General Practitioner (GP), patients can wait anywhere from a few months to as long as three years to begin treatment. ⁴⁵ A 2024 survey by the Human Fertilisation and Embryology Authority (HFEA) painted a clear picture of this disparity: only 35% of NHS patients start treatment within a year of seeing their GP, compared to 53% of self-funded patients. A concerning 16% of NHS patients wait for more than two years. ¹³ Similarly, in Ontario, Canada, wait times for government-funded IVF cycles are notoriously long and clinic-dependent, ranging from a manageable 3 months at some clinics to a staggering 24 months or more at others. ⁵⁶ Patients have reported being on a waitlist for 18 months, only to find they were still not close to receiving treatment. ⁵⁵ In stark contrast, privately paid cycles in both countries often have "minimal wait times," with the main delay being the one to three months required to secure an initial consultation. ⁵⁴

• Clinical Implications: This disparity in timing has profound clinical consequences. Fertility, particularly female fertility, is intrinsically time-sensitive. Success rates for IVF decline with age, with a significant drop after the age of 35. ⁶⁵ A wait of 18 to 24 months can be the difference between a successful pregnancy and irreversible infertility. This reality effectively forces older patients, or those diagnosed with conditions like diminished ovarian reserve, to either pay for private treatment or abandon their hopes of parenthood. ⁴⁷ In this context, a long waitlist is not just an administrative delay; it is a form of rationing that actively reduces the likelihood of a successful clinical outcome for those who cannot afford to bypass it. The two-tier system, therefore, institutionalizes a two-tier standard of clinical outcomes based on wealth.

The Patient Experience: Navigating Inequity

The journey through a two-tier system is often fraught with frustration, confusion, and a sense of injustice.

• The Two-Tier System as a Driver of Inequality: These systems create a clear and often painful divide based on the ability to pay. Those with financial means can purchase speed and access, while others are left in a queue, a situation that many argue contradicts the foundational principles of universal healthcare systems like the NHS. ⁶⁷

• Geographic and Demographic Disparities: Access is not just about money; it is also about geography and identity. The UK's "postcode lottery" means that a patient's access to public funds is determined by their home address, not their medical need. ⁴² Canada's "provincial patchwork" creates similar geographic inequities. ¹ Furthermore, eligibility rules often create discriminatory hurdles for certain groups. In the UK, single women and same-sex female couples have historically been required to self-fund multiple cycles of IUI to "prove" their infertility before qualifying for NHS-funded IVF—a financial barrier estimated at over £20,000 that heterosexual couples do not face. ⁶⁹ While the UK government has committed to removing this requirement, its implementation has been inconsistent. ⁷⁰

• The Emotional and Psychological Burden: The process itself can be deeply stressful. Patients report feeling like they are in a "lottery," with a profound lack of transparency from clinics regarding their position on a waitlist or the criteria used for allocation. ⁷¹ This opacity and inconsistency motivates patients to engage in "clinic shopping," placing their names on multiple waitlists in the hope of securing a funded spot sooner, a behavior that further complicates and burdens the system. ⁷³ The emotional toll of waiting, uncertainty, and navigating a complex bureaucracy is immense. Many patients feel powerless and are reluctant to raise concerns or complain, fearing it could damage their relationship with the very clinic they depend on for a chance at parenthood. ⁷⁴

• Racial Disparities: The inequities are also racialized. Evidence from the HFEA survey in the UK reveals significant disparities in patient satisfaction. While 73% of patients overall were satisfied, this figure dropped to just 50% for Asian patients and 59% for Black patients. ¹³ These groups also reported lower satisfaction with the quality of information provided by their clinics. This dissatisfaction may be linked to documented lower IVF success rates and poorer access to NHS funding for these ethnic groups. ¹³

Ultimately, the architecture of the two-tier system creates a perverse incentive structure. While public funding is well-intentioned, its flawed implementation—specifically the long delays—inadvertently serves as a powerful marketing funnel for the private sector. The existence of a "free" but slow public option validates the medical necessity of IVF in the public consciousness, while the long wait times create a captive market of desperate, time-sensitive patients for private clinics to target. This dynamic is evident in how private clinics in the UK and Canada explicitly market their "shorter waiting times" and "no waiting lists" as a primary benefit and a direct solution to the public system's most significant failing. ⁷⁵ The state funds the idea of access, while the private market profits from the failure of its timely delivery.

Section 5: Fertility Tourism: A Global Market Driven by Cost and Regulation

The combination of high costs, restrictive regulations, and unequal access in many developed nations has given rise to a global phenomenon: fertility tourism, or Cross-Border Reproductive Care (CBRC). Patients are increasingly traveling to other countries in search of more affordable, accessible, or legally permissible treatments.

Primary Drivers of Cross-Border Reproductive Care (CBRC)

The decision to travel for fertility treatment is typically driven by a combination of powerful "push" and "pull" factors.

• Cost Arbitrage: This remains the most significant driver. The vast price differences for an IVF cycle—from over $25,000 in the US to under $4,000 in India—create a powerful financial incentive to travel.³ Patients from high-cost countries like the United States can save tens of thousands of dollars by seeking treatment in destinations like Mexico, the Czech Republic, or India.¹⁹ This is also a key motivator for UK patients who are ineligible for NHS funding and find domestic private care to be prohibitively expensive.⁷⁷

• Circumventing Legal and Regulatory Restrictions: A country's laws on ART are a major push factor. Patients travel to access services that are illegal, heavily restricted, or unavailable in their home country.⁷⁸ Key areas of legal difference include:

  • Surrogacy: Commercial surrogacy is banned in many European countries, including Spain and, until recently, Greece.⁸¹ This forces intended parents to travel to jurisdictions with established legal frameworks for surrogacy, such as certain states in the US or Canada.

  • Donor Anonymity: The legal status of gamete donors varies widely. Patients from the UK, where donors must be identifiable to offspring at age 18, may travel to Spain or the Czech Republic specifically to access anonymous donors.⁸³ Conversely, patients from countries with mandatory anonymity may seek treatment in places that allow for non-anonymous or "open" donation.

  • Access for Single Women and Same-Sex Couples: Restrictive laws in some nations, such as Turkey, which only permits treatment for married heterosexual couples, push single women and LGBTQ+ individuals to more liberal destinations like Spain, Portugal, or Denmark.³³

  • Advanced Technologies: The availability of specific technologies can also drive tourism. For example, PGT for non-medical gender selection is banned in countries like the UK and Canada but is available in others, such as North Cyprus and Mexico, making them destinations for patients seeking this service.⁷⁸

• Access and Availability: Beyond cost and legality, simple availability is a powerful motivator. In many countries, long waiting lists for public treatment or shortages of suitable egg or sperm donors push patients to look abroad where they can access treatment or find a donor match more quickly.²⁰

Mapping the Destinations: A Global Hub Analysis

A distinct map of fertility tourism destinations has emerged, with each hub offering a unique value proposition.

• Spain: Often considered the "gold standard" of European fertility tourism, Spain combines high-quality care, advanced technology, and a liberal and well-regulated legal framework that allows for donor anonymity and treatment for single women and LGBTQ+ individuals.³⁷

• Czech Republic & Greece: These are the "value proposition" hubs of Europe, offering EU-standard care at a significantly lower cost than in Western Europe.³⁷ Greece is known for its high legal age limit for treatment (54), while the Czech Republic is respected for its clinical rigor and affordability.³⁷ However, it is crucial to note that recent legal changes have impacted these destinations. A major scandal involving a clinic in Crete led Greece to amend its law in May 2025, now requiring both the intended parent and the surrogate to be legal residents, effectively closing the country to new international surrogacy arrangements.⁸⁶

• North Cyprus & Turkey: These destinations are popular for their more permissive regulations and lower costs. North Cyprus allows treatment for women up to age 55 and permits gender selection.⁸⁰ Turkey offers very low costs but is highly restrictive, permitting treatment only for married heterosexual couples using their own gametes.³⁷

• India & Thailand: These are major Asian hubs known for offering some of the lowest treatment costs in the world, making them highly attractive for cost-driven medical travel.¹⁹

Navigating the Legal and Ethical Maze

While fertility tourism offers solutions, it also exposes patients to significant legal, medical, and ethical risks in what is often a poorly regulated global space.

• The Surrogacy Quagmire: Surrogacy is by far the most legally complex and perilous area of CBRC. The legal landscape is volatile and constantly shifting. Spain recently implemented a ban on its embassies and consulates registering children born via surrogacy abroad, forcing parents into complex adoption or biological parentage proceedings upon return.⁸¹ The Czech Republic has no explicit law governing surrogacy, meaning any contract is legally unenforceable, placing all parties in a precarious legal gray area.⁸⁹ These legal voids create immense risk for intended parents, who can face protracted and expensive legal battles over the parentage and citizenship of their child, potentially leaving the child "marooned, stateless, and parentless".¹⁹

• Regulatory Voids and Quality Concerns: There is no unified international framework governing ART.⁹² When patients travel, they often leave the highly regulated and transparent environments of bodies like the UK's HFEA for jurisdictions with potentially lax oversight.⁸⁴ This raises critical concerns about clinic accreditation, the veracity of advertised success rates, the ethical sourcing of gametes, and overall standards of care.⁹²

• The Commodification Debate: CBRC raises profound ethical questions about the commodification of the human body and reproduction.⁹⁴ There are significant concerns about the potential exploitation of economically vulnerable women who act as egg donors or gestational carriers in lower-income countries to serve a clientele from wealthier nations.⁹²

This analysis reveals a paradox of regulation. Attempts by developed nations to enforce high ethical standards—such as banning commercial surrogacy in Spain or mandating non-anonymous donation in the UK—do not eliminate the demand for these services. Instead, these regulations often have the unintended consequence of exporting the ethical dilemma. Patients, driven by a powerful desire for a child, simply cross borders to jurisdictions with laxer rules. This does not solve the ethical problem; it merely displaces it to a global, often unregulated space, potentially increasing the risks for all involved—patients, donors, surrogates, and most importantly, the children born from these arrangements. The most regulated markets inadvertently fuel the least regulated ones.

Conclusion and Recommendations

The global landscape of In Vitro Fertilization is not a collection of independent markets but a deeply interconnected system where the cost, accessibility, and regulation of treatment are dictated by national policy choices. The dream of parenthood, once a private journey, is now a globalized pursuit, with access determined by a complex calculus of citizenship, income, and a willingness to navigate international borders and legal gray areas.

Synthesis of Key Findings

This report has established several critical conclusions:

1. The "true cost" of IVF is a multi-cycle, multi-component expense that far exceeds the often-misleading advertised prices. The financial reality for most patients is not a single large payment but a prolonged series of substantial outlays, a fact that is central to the business model of many private clinics.

2. Affordability is relative, not absolute. Countries with the lowest absolute costs, like India, can be catastrophically unaffordable for their own citizens. This affordability paradox shapes their domestic market structure, gearing it towards a small local elite and a large international clientele. Conversely, treatment in high-income nations with public support, like Denmark or Japan, is far more manageable for the local population.

3. Two-tier funding systems, while intended to broaden access, often create systemic inequities. The long waiting lists for public care in countries like the UK and Canada function as a form of rationing that disadvantages those who cannot afford to pay for speed. This dynamic creates a private market that profits directly from the public system's limitations, institutionalizing a two-tier standard of clinical outcomes based on wealth.

4. Fertility tourism is a rational, albeit risky, response by patients to these domestic barriers. The global flow of patients is a direct mirror of the legislative and economic policies of their home countries. Every restriction or high cost in a "source" nation creates a corresponding market opportunity in a "destination" nation. However, this pursuit of solutions exposes patients to significant legal, medical, and ethical risks in a largely unregulated global space.

The ultimate conclusion is that the policy choices made in one nation directly create the market conditions and patient behaviors in another. The attempt to enforce high ethical standards domestically, without addressing the underlying demand, can have the perverse effect of pushing citizens towards riskier, less-regulated environments abroad.

Actionable Recommendations

Based on this analysis, the following recommendations are proposed for key stakeholders.

For Prospective Patients:

• Due Diligence is Paramount: Before committing to any clinic, domestic or foreign, conduct exhaustive research. Look for official accreditation, independently validated success rates, and be deeply skeptical of marketing claims that seem too good to be true.⁹² Understand that success rates are influenced by many factors, including patient age and diagnosis, and are not always comparable between clinics or countries.⁶⁶

• Understand the "All-In" Cost: Demand a fully itemized quote from any clinic you consider. Ask specifically what is not included in the base price (e.g., medications, PGT, anesthesia, cryopreservation, annual storage). Critically, budget for the realistic possibility of needing two to three cycles to achieve success.⁹

• Seek Independent Legal Counsel: This is non-negotiable for anyone considering cross-border surrogacy or donor arrangements. You must consult with qualified legal experts in both your home country and the destination country before initiating any treatment. This is the only way to understand the potential challenges related to legal parentage, citizenship, and your ability to return home with your child.⁷⁹

For Policymakers:

• Address the Root Causes of Fertility Tourism: Recognize that restrictive domestic policies, high costs, and inequitable public funding are the primary drivers of risky cross-border care. Expanding equitable, timely, and affordable access to ART at home is the single most effective patient safety measure.

• Improve Transparency in Two-Tier Systems: To mitigate the "postcode lottery" and "clinic shopping" phenomena, governments should mandate clear, centralized, and public reporting of wait times, allocation criteria, and success rates for publicly funded programs. This would reduce patient frustration and allow for more informed decision-making.⁷²

• Promote International Cooperation and Harmonization: The challenges of CBRC cannot be solved by unilateral national policies alone. Governments should work through international bodies to establish minimum standards for ART regulation, transparent data reporting, and the legal and ethical protection of all parties involved—patients, gamete donors, gestational carriers, and the children born from these arrangements. Addressing the legal status of children born via international surrogacy is a particularly pressing problem that requires a coordinated global response.¹⁹

Works cited

1. Provincial coverage | Fertility Matters Canada, accessed July 16, 2025, https://www.fertilitymatters.ca/learn/funding/provincial-coverage/

2. Medical Reproductive Tourism | IVF - CCRM Fertility, accessed July 16, 2025, https://www.ccrmivf.com/blog/fertility-tourism/

3. Understanding the Cost of IVF in 2024 | ARC Fertility, accessed July 16, 2025, https://www.arcfertility.com/patient-resources/understanding-the-cost-of-ivf/

4. How Much Does IVF Cost? FET & IVF Cost Breakdown - CCRM Fertility, accessed July 16, 2025, https://www.ccrmivf.com/ivf-cost/

5. How Much Does IVF Cost in the UK? | Fertility Mapper, accessed July 16, 2025, https://fertilitymapper.com/fertility/cost/ivf/

6. How Much Does IVF Cost in London? | Fertility Mapper, accessed July 16, 2025, https://fertilitymapper.com/fertility/cost/ivf/london/

7. IVF Treatment Cost in Canada - Chandigarh, accessed July 16, 2025, https://www.ivfchandigarh.com/services/ivf-treatment-cost-in-canada

8. How Much Does IVF Treatment Cost in India? - Ankoor Fertility Clinic, accessed July 16, 2025, https://ankoorfertilityclinicmumbai.com/how-much-does-ivf-treatment-cost-in-india/

9. The Cost of IVF By City - FertilityIQ, accessed July 16, 2025, https://www.fertilityiq.com/fertilityiq/articles/the-cost-of-ivf-by-city

10. IVF Treatment Cost - Check Various Costs Related to Cycles, Tech & More | Melbourne IVF, accessed July 16, 2025, https://www.mivf.com.au/ivf-costs/costs-of-ivf

11. How Much Does IVF Cost in India 2024? - Vardaan Medical Center, accessed July 16, 2025, https://vardaanmedicalcenter.com/blog/how-much-does-ivf-cost-in-india-2024/

12. How Much Does IVF Cost in Australia? - Canstar, accessed July 16, 2025, https://www.canstar.com.au/health-insurance/ivf-cost/

13. Fertility patients' satisfaction with treatment is high but room for improvement remains, says HFEA, accessed July 16, 2025, https://www.hfea.gov.uk/about-us/news-and-press-releases/2025/fertility-patients-satisfaction-with-treatment-is-high-but-room-for-improvement-remains-says-hfea/

14. IVF In Spain: Costs, Reviews, Success Rates - Fertility Road, accessed July 16, 2025, https://fertilityroad.com/ivf-abroad/ivf-spain/

15. Egg Donation in Spain: 2025 Costs, Availability & Clinics, accessed July 16, 2025, https://www.eggdonationfriends.com/ivf-egg-donation-country-spain/

16. IVF In Denmark: 2025 Costs, Reviews, Success Rates - Fertility Road, accessed July 16, 2025, https://fertilityroad.com/ivf-abroad/ivf-in-denmark/

17. Egg Donation in Denmark: Costs, Availability & Clinics, accessed July 16, 2025, https://www.eggdonationfriends.com/ivf-egg-donation-country-denmark/

18. Impact of insurance coverage on access to assisted reproductive technology: A nationwide survey in Japan (the IZANAMI project), accessed July 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11997234/

19. Fertility tourism - Wikipedia, accessed July 16, 2025, https://en.wikipedia.org/wiki/Fertility_tourism

20. Fertility tourism: Why travel abroad? - Cryos International, accessed July 16, 2025, https://www.cryosinternational.com/en-gb/dk-shop/private/blog/fertility-tourism-why-travel-abroad/

21. Disposable household and per capita income - Wikipedia, accessed July 16, 2025, https://en.wikipedia.org/wiki/Disposable_household_and_per_capita_income

22. Income in India - Wikipedia, accessed July 16, 2025, https://en.wikipedia.org/wiki/Income_in_India

23. Cost of living in Index By Country in 2025: Clothing, Food, Housing & More - Wise, accessed July 16, 2025, https://wise.com/gb/cost-of-living/index-by-country

24. India's Per Capita Income in 2022-23 - India Briefing, accessed July 16, 2025, https://www.india-briefing.com/news/indias-per-capita-income-doubles-since-2014-15-but-wealth-unevenly-spread-27325.html/

25. Best Countries for IVF Success - Universal Medical Travel, accessed July 16, 2025, https://universalmedicaltravel.com/best-countries-for-ivf-in-the-world/

26. India IVF secures $1.25 million pre-series a funding from Tomorrow Capital for north India expansion - Express Healthcare, accessed July 16, 2025, https://www.expresshealthcare.in/news/india-ivf-secures-1-25-million-pre-series-a-funding-from-tomorrow-capital-for-north-india-expansion/446845/

27. India IVF, one of India's First Tech-Enabled Fertility Platform, Secures $1.25 Million Investment from Tomorrow Capital - PR Newswire, accessed July 16, 2025, https://www.prnewswire.com/in/news-releases/india-ivf-one-of-indias-first-tech-enabled-fertility-platform-secures-1-25-million-investment-from-tomorrow-capital-302301045.html

28. India IVF Secures USD 1.25 Mn from Tomorrow Capital | Entrepreneur, accessed July 16, 2025, https://www.entrepreneur.com/en-in/news-and-trends/india-ivf-secures-usd-125-mn-from-tomorrow-capital/482766

29. BabyQuest Foundation | In Vitro Fertilization Financial Aid, accessed July 16, 2025, https://babyquestfoundation.org/

30. Free IVF Treatment in India 2025 - Government Schemes Guide - World Fertility Services, accessed July 16, 2025, https://worldfertilityservices.com/blog/free-ivf-treatment-in-which-state/

31. How much does IVF Cost in India? (Updated Per IVF Cycle in November 2024), accessed July 16, 2025, https://drnaliniguptaivf.com/ivf-cost-in-india/

32. About Endowment - ISAR Dr Sadhana Desai Endowment Fund Initiative., accessed July 16, 2025, https://isarindia.net/isar_ivf/about-endowment-fund.php

33. Spain expands IVF provision to cover single women and LGBTQ+ community | PET, accessed July 16, 2025, https://www.progress.org.uk/spain-expands-ivf-provision-to-cover-single-women-and-lgbtq-community/

34. Spain expands IVF to lesbians, single women, trans people | AP News, accessed July 16, 2025, https://apnews.com/article/lifestyle-europe-health-public-health-spain-2cf8223a7a113734aa7dbbd82b6eb73c

35. Women Up To 45 Can Now Get Free IVF in Madrid | The Surrogacy Law Center, accessed July 16, 2025, https://surrogacy-lawyer.com/women-up-to-45-can-now-get-free-ivf-in-madrid/

36. Does Social Security in Spain cover fertility treatments or in vitro f, accessed July 16, 2025, https://excellencefertility.com/en/blogs/camino-a-la-fertilidad/la-seguridad-social-en-espana-cubre-los-tratamientos-de-fertilidad-o-fecundacion-in-vitro

37. Fertility Tourism Hotspots - Fertility Road, accessed July 16, 2025, https://fertilityroad.com/treatment-options-abroad/fertility-tourism-new-frontier/

38. Fertility treatment via a public health referral at Trianglen, accessed July 16, 2025, https://www.trianglen.dk/en/fertility-treatments-services/prices/free-fertility-treatment

39. Free fertility treatment for the first and second child in cooperation with the Danish Regions, accessed July 16, 2025, https://www.aagaardklinik.dk/en/news/free-fertility-treatment-for-the-first-and-second-child-in-cooperation-with-the-danish-regions

40. Denmark's Fertility Landscape Transforms Once Again: A Promising Future For ART Clinics, accessed July 16, 2025, https://www.coopersurgical.com/news/denmarks-fertility-landscape-transforms-once-again-a-promising-future-for-art-clinics/

41. Don't Give Up Hope For A Biological Baby: How to Get Fertility Support in Denmark, accessed July 16, 2025, https://lwid.dk/dont-give-up-hope-for-a-biological-baby-how-to-get-fertility-support-in-denmark/

42. IVF NHS Funding Eligibility | How It Works - Care Fertility, accessed July 16, 2025, https://carefertility.com/costs/how-do-i-pay/ivf-nhs-funding

43. NHS funding | Fertility Network, accessed July 16, 2025, https://fertilitynetworkuk.org/access-support/nhs-funding/

44. Costs and funding - HFEA, accessed July 16, 2025, https://www.hfea.gov.uk/treatments/explore-all-treatments/costs-and-funding/

45. Am I Eligible for IVF on the NHS? Criteria & Eligibility - Fertility Mapper, accessed July 16, 2025, https://fertilitymapper.com/fertility/nhs/am-i-eligible-for-ivf-on-the-nhs/

46. IVF - NHS, accessed July 16, 2025, https://www.nhs.uk/tests-and-treatments/ivf/

47. Private fertility clinics & NHS IVF provision - Access Fertility UK, accessed July 16, 2025, https://www.accessfertility.com/blog/nhs-ivf-provision-private-fertility-clinics/

48. New research shows lack of NHS cash forcing IVF patients into private care they can't afford - Queen Mary University of London, accessed July 16, 2025, https://www.qmul.ac.uk/media/news/2023/hss/new-research-shows-lack-of-nhs-cash-forcing-ivf-patients-into-private-care-they-cant-afford.html

49. Fertility treatments on the up, but not via NHS as more opt for private pathway - Sky News, accessed July 16, 2025, https://news.sky.com/story/fertility-treatments-on-the-up-but-not-via-nhs-as-more-opt-for-private-pathway-12905723

50. Ontario Helping More Families Access Fertility Supports, accessed July 16, 2025, https://news.ontario.ca/en/release/1006038/ontario-helping-more-families-access-fertility-supports

51. Publicly funded in-vitro fertilization (IVF) program - Province of British Columbia - Gov.bc.ca, accessed July 16, 2025, https://www2.gov.bc.ca/gov/content/health/accessing-health-care/publicly-funded-ivf-program

52. Province launches program to fund IVF, support families - BC Gov News, accessed July 16, 2025, https://news.gov.bc.ca/releases/2025HLTH0065-000639

53. Applications for B.C.'s publicly funded IVF program now open | CBC News, accessed July 16, 2025, https://www.cbc.ca/news/canada/british-columbia/ivf-program-bc-1-round-1.7574979

54. In-Vitro Fertilization (IVF) Wait times - Ottawa Fertility Centre, accessed July 16, 2025, https://conceive.ca/wp-content/uploads/2022/01/IVF-Waiting-Times-Patient-Handout-En-29-Oct-2020.pdf

55. Access to IVF a challenge for many due to long wait lists - CANADIAN AFFAIRS, accessed July 16, 2025, https://www.canadianaffairs.news/2024/02/09/access-to-ivf-a-challenge-for-many-due-to-long-wait-lists/

56. IVF Waitlist in Ontario: What To Expect (2025) - Fertility Finder Canada, accessed July 16, 2025, https://fertilityfinder.ca/ivf-waitlist-in-ontario-what-to-expect/

57. Medicare Rebate & IVF Costs - Check What is & isn't Included | Melbourne IVF, accessed July 16, 2025, https://www.mivf.com.au/ivf-costs/medicare-rebate

58. How much does IVF cost and does Medicare cover it? - Fertility News, accessed July 16, 2025, https://news.flindersfertility.com.au/how-much-does-ivf-cost-and-does-medicare-cover-it

59. Public Fertility Care | health.vic.gov.au, accessed July 16, 2025, https://www.health.vic.gov.au/public-health/public-fertility-care

60. Japan, in need of more babies, is helping pay for costly IVF, accessed July 16, 2025, https://www.japantimes.co.jp/news/2022/04/01/national/japan-ivf-support/

61. Japanese Health Insurance Coverage of Fertility Treatment in 2022: Does Coverage Change Patient Perspectives? - PMC, accessed July 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11669821/

62. 70% of Japan's major local governments offer financial assistance for fertility treatment, accessed July 16, 2025, https://asianews.network/70-of-japans-major-local-governments-offer-financial-assistance-for-fertility-treatment/

63. Treatment for infertility - NHS, accessed July 16, 2025, https://www.nhs.uk/conditions/infertility/treatment/

64. How Long is the IVF Waiting List in the UK? - GlobMed, accessed July 16, 2025, https://globmed.co.uk/blog/how-long-ivf-waiting-list-uk/

65. IVF Success Rates & Fertility Statistics | Pacific Fertility Center, accessed July 16, 2025, https://www.pacificfertilitycenter.com/the-center/ivf-success-rates

66. IVF Success Rate By Country - Fertility Road, accessed July 16, 2025, https://fertilityroad.com/ivf/ivf-success-rates-explained/

67. BPAS - Fertility Investigation NHS Funded Fertility Care for Female Same Sex Couples, accessed July 16, 2025, https://www.bpas.org/media/3484/bpas-fertility-investigation-nhs-funded-fertility-care-for-female-same-sex-couples.pdf

68. Two-tier system: Private health insurer fills gap in B.C.'s infertility treatment care - CTV News, accessed July 16, 2025, https://www.ctvnews.ca/vancouver/article/two-tier-system-private-health-insurer-fills-gap-in-bcs-infertility-treatment-care/

69. Fertility treatment is two-tier system – and single women are paying the price | The Independent, accessed July 16, 2025, https://www.independent.co.uk/life-style/women/single-women-fertility-ivf-uk-b2659551.html

70. General debate: IVF provision - UK Parliament, accessed July 16, 2025, https://researchbriefings.files.parliament.uk/documents/CDP-2023-0194/CDP-2023-0194.pdf

71. Frequently asked questions - Fertility specialist Montreal & Quebec - Clinique Ovo, accessed July 16, 2025, https://www.cliniqueovo.com/en/services/fertility-services/frequently-asked-questions

72. Patients' perspectives on allocation of publicly funded in vitro fertilization in Ontario: a qualitative study - PubMed Central, accessed July 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6559882/

73. The Impact of the Ontario Fertility Program on Duplicate Fertility Consultations - PMC, accessed July 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7008682/

74. Patients' experiences of buying fertility treatment - GOV.UK, accessed July 16, 2025, https://assets.publishing.service.gov.uk/media/632c2fefe90e073721b08402/Consumer_research_report_160922.pdf

75. Understanding NHS Fertility Referral Timelines - Kind IVF, accessed July 16, 2025, https://www.kindivf.com/blog/understanding-nhs-fertility-referral-timelines/

76. How is Private IVF Treatment Different from the NHS? | IVF Fertility London, accessed July 16, 2025, https://www.conceptfertility.co.uk/2020/02/17/how-is-private-ivf-treatment-different-from-the-nhs/

77. IVF Treatment Costs In The UK - Fertility Road, accessed July 16, 2025, https://fertilityroad.com/ivf/ivf-costs-uk-revealed/

78. What are the reasons behind people using fertility tourism? - New Life Mexico, accessed July 16, 2025, https://www.newlifemexico.net/reasons-behind-people-using-fertility-tourism/

79. Cross-border reproductive care: an Ethics Committee opinion (2022), accessed July 16, 2025, https://www.asrm.org/practice-guidance/ethics-opinions/cross-border-reproductive-care-an-ethics-committee-opinion-2022/

80. Fertility Treatment Abroad - The IVF Warrior, accessed July 16, 2025, https://www.theivfwarrior.ca/fertility-tourism/fertility-abroad

81. Navigating Spain's Surrogacy Ban for Families - Conceptual Options, accessed July 16, 2025, https://www.conceptualoptions.com/navigating-spains-surrogacy-ban-for-families/

82. Surrogacy in Greece - Growing Families, accessed July 16, 2025, https://www.growingfamilies.org/surrogacy-in-greece/

83. Fertility Tourism - Top Destinations and Process, accessed July 16, 2025, https://www.fertilityclinicsabroad.com/ivf-clinics-abroad/fts-2020/

84. Fertility treatment abroad and the wider legal and regulatory complexities - NCBI, accessed July 16, 2025, https://www.ncbi.nlm.nih.gov/books/NBK263152/

85. Best Countries for IVF – Top 10 Global Destinations for Fertility Treatment, accessed July 16, 2025, https://www.placidway.com/article/1413/10-Top-Fertility-Tourism-Countries

86. Major Change to Greek Surrogacy Laws: What It Means for International Intended Parents, accessed July 16, 2025, https://www.growingfamilies.org/blog/major-change-to-greek-surrogacy-laws-what-it-means-for-international-intended-parents/

87. Shifting Surrogacy Laws in Spain: What Do They Mean?, accessed July 16, 2025, https://www.americansurrogacy.com/blog/shifting-surrogacy-laws-in-spain/

88. Denying Legal Parentage: A Step Backward for Surrogacy in Spain, accessed July 16, 2025, https://oneill.law.georgetown.edu/denying-legal-parentage-a-step-backward-for-surrogacy-in-spain/

89. gov.cz - Public administration portal, accessed July 16, 2025, https://portal.gov.cz/en/informace/surrogacy-INF-25

90. www.gestlifesurrogacy.com, accessed July 16, 2025, https://www.gestlifesurrogacy.com/en/surrogacy-in-czech-republic/#:~:text=Czech%20legislation%20does%20not%20explicitly,contract%20would%20be%20absolutely%20invalid.

91. I want to use surrogacy | Repromeda, accessed July 16, 2025, https://www.repromeda.com/i-want-to-use-surrogate-motherhood/

92. Navigating Fertility Tourism Laws - Number Analytics, accessed July 16, 2025, https://www.numberanalytics.com/blog/fertility-tourism-reproductive-rights-law

93. IVF without borders - taking fertility overseas - ITIJ, accessed July 16, 2025, https://www.itij.com/latest/long-read/ivf-without-borders-taking-fertility-overseas

94. Use of in vitro fertilization—ethical issues - PMC, accessed July 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7721055/

95. Effective May 1, 2025 - Spain Bans Embassies and Consulates From Registering Babies Born Through Surrogacy - Greenspoon Marder LLP, accessed July 16, 2025, https://www.gmlaw.com/news/effective-may-1-2025-spain-bans-embassies-and-consulates-from-registering-babies-born-through-surrogacy/

. . .

CARE Fertility and Women’s Health is a leading fertility clinic, offering personalized care and advanced reproductive technology to help individuals and couples achieve their dream of parenthood. With state-of-the-art genetic testing, individualized treatment plans, and holistic support, we specialize in complex fertility cases and boast some of the highest success rates in Canada. 

Stay Informed! 

Follow us on social media for fertility tips, patient stories, and the latest advancements in fertility care. Facebook | Instagram | LinkedIn | X | TikTok | YouTube